4.7 Review

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza

Journal

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 16, Issue 5, Pages E321-E331

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2012.01.003

Keywords

Influenza, human; Pneumonia, bacterial; Antiviral agents; Influenza A virus; Antibacterial agents

Funding

  1. Wyeth
  2. Pfizer Inc.
  3. Pfizer
  4. Astellas
  5. AstraZeneca
  6. Cempra
  7. Cerexa/Forest
  8. Medicines Company
  9. Boehringer Ingelheim
  10. Gilead
  11. Tibotec
  12. GlaxoSmithKline

Ask authors/readers for more resources

Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia. (C) 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available